Development of an electrochemiluminescence immunoassay for quantitative determination of semaglutide in human serum
Analytical Biochemistry · 2026-07 · 714 · 116115
DOI: 10.1016/j.ab.2026.116115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Biochemistry, 2026-07. Verfasst von Yifan Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wenzhou Medical University, Wenzhou City, 325024, Zhejiang province, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou Cit…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Luminescent Measurements, Electrochemical Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: University of Chinese Academy of Sciences, University of the Chinese Academy of Sciences Wenzhou Institute.
Abstract (Originalsprache)
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), is widely used in the treatment of patients with type 2 diabetes mellitus and obesity. A sensitive and reliable quantification method is essential for bioanalysis of semaglutide in clinical studies. To develop a sensitive and specific immunoassay, we have prepared a pair of highly specific anti-semaglutide monoclonal antibodies and subsequently employed them as critical reagents in the development of an electrochemiluminescence immunoassay (ECLIA) for the quantification of semaglutide levels in human serum. The assay validation data presented here demonstrate that the performance of the ECLIA method meets prespecified criteria for all validation parameters within the quantitative range of 0.5 ng/mL to 200.0 ng/mL. The intra- and inter-assay precision (%CV) are both ≤14.4%, and accuracy (%RE) ranges from -12.5% to 15.3%. No interference is found with recombinant human GLP-1 as the endogenous counterpart, confirming the assay specificity. Additional assay performance parameters, including selectivity, dilutional linearity, hook effect, and sample stability, all meet the acceptance criteria preset in accordance with international guidelines for bioanalytical method validation. The method is suitable for bioanalysis of semaglutide in human serum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wenzhou Medical University, Wenzhou City, 325024, Zhejiang province, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou City, 325038, Zhejiang province, China.
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou City, 325038, Zhejiang province, China. Electronic address: hefengzhang@ucas.ac.cn.
- Wenzhou Medical University, Wenzhou City, 325024, Zhejiang province, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou City, 325038, Zhejiang province, China; Wenzhou KanryBio Biotech Co., Ltd…
Förderung
- University of Chinese Academy of Sciences
- University of the Chinese Academy of Sciences Wenzhou Institute
Zitieren
APA
Luo, Y., Zhang, J., Chen, W., Zhang, H., & Zou, L. (2026). Development of an electrochemiluminescence immunoassay for quantitative determination of semaglutide in human serum. Analytical Biochemistry, 714, 116115. https://doi.org/10.1016/j.ab.2026.116115
Vancouver
Luo Y, Zhang J, Chen W, Zhang H, Zou L. Development of an electrochemiluminescence immunoassay for quantitative determination of semaglutide in human serum. Analytical Biochemistry. 2026;714:116115. doi:10.1016/j.ab.2026.116115
BibTeX
@article{Luo2026,
author = {Luo, Yifan and Zhang, Junyan and Chen, Wenlong and Zhang, Hefeng and Zou, Linglong},
title = {Development of an electrochemiluminescence immunoassay for quantitative determination of semaglutide in human serum},
journal = {Analytical Biochemistry},
year = {2026},
volume = {714},
pages = {116115},
doi = {10.1016/j.ab.2026.116115}
}
EUVIMED